Nonarteritic anterior ischemic optic neuropathy
Disease4 papers9 findings
A human trial links liraglutide and semaglutide to higher nonarteritic anterior ischaemic optic neuropathy risk than with non-GLP-1RA treatments. A pharmacovigilance analysis in the same paper associates both drugs with the condition, and a separate human trial reports an association with semaglutide.
- Humans1
Interventions
1GLP-1 receptor agonists
no changein humans1HR 1.86Low certainty
1 study
GLP-1 receptor agonists
no changein humans1HR 1.86Low certainty
GLP-1 receptor agonists have no effect on nonarteritic anterior ischemic optic neuropathy in humans (HR: 1.86; 95% CI: 0.84-4.09).
Humansin patients with type 2 diabetes
Glucagon-Like Peptide-1 Receptor Agonist Use and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients with Type 2 Diabetes · Ophthalmology. Retina · 3 Sep 2026
Associations
3Semaglutide
upin humans2HR 1.538High certainty
2 studies
Semaglutide
upin humans2HR 1.538High certainty
Semaglutide is associated with nonarteritic anterior ischemic optic neuropathy in humans (ROR = 94.534, 95% CI: 83.093-107.552).
HumansFAERS pharmacovigilance analysis
Comparative Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Among Glucagon-Like Peptide-1 Receptor Agonists: An Integrated Safety and Mechanistic Analysis · Diabetes, obesity & metabolism · 21 Sep 2026
Semaglutide raises the risk of nonarteritic anterior ischemic optic neuropathy in humans (HR = 1.538, 95% CI: 1.305-1.816).
Human trialcompared with non-GLP-1RA treatments
Comparative Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Among Glucagon-Like Peptide-1 Receptor Agonists: An Integrated Safety and Mechanistic Analysis · Diabetes, obesity & metabolism · 21 Sep 2026
Semaglutide is associated with nonarteritic anterior ischemic optic neuropathy in humans.
Human trialin a patient with obesity, diabetes mellitus, hypertension, dyslipidemia, and rapid weight loss2 monthsmalesn = 1
Nonarteritic anterior ischemic optic neuropathy after rapid weight loss during semaglutide therapy: a case report · Korean journal of family medicine · 18 Sep 2026
Liraglutide
upin humans2HR 1.251High certainty
2 studies
Liraglutide
upin humans2HR 1.251High certainty
Liraglutide is associated with nonarteritic anterior ischemic optic neuropathy in humans (ROR = 4.519, 95% CI: 2.617-7.802).
HumansFAERS pharmacovigilance analysis
Comparative Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Among Glucagon-Like Peptide-1 Receptor Agonists: An Integrated Safety and Mechanistic Analysis · Diabetes, obesity & metabolism · 21 Sep 2026
Liraglutide raises the risk of nonarteritic anterior ischemic optic neuropathy in humans (HR = 1.251, 95% CI: 1.080-1.450).
Human trialcompared with non-GLP-1RA treatments
Comparative Risk of Nonarteritic Anterior Ischemic Optic Neuropathy Among Glucagon-Like Peptide-1 Receptor Agonists: An Integrated Safety and Mechanistic Analysis · Diabetes, obesity & metabolism · 21 Sep 2026
Liraglutide raises the risk of nonarteritic anterior ischemic optic neuropathy in humans.
Humanswithin 12 or 18 months of follow-up in patients with type 2 diabeteswithin 12 or 18 months
Glucagon-Like Peptide-1 Receptor Agonist Use and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients with Type 2 Diabetes · Ophthalmology. Retina · 3 Sep 2026
GLP-1 receptor agonists
upin humans2Low certainty
2 studies
GLP-1 receptor agonists
upin humans2Low certainty
GLP-1 receptor agonists raise the risk of nonarteritic anterior ischemic optic neuropathy in humans.
Humansin patients with type 2 diabetesmales
Glucagon-Like Peptide-1 Receptor Agonist Use and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients with Type 2 Diabetes · Ophthalmology. Retina · 3 Sep 2026
GLP-1 receptor agonists are associated with nonarteritic anterior ischemic optic neuropathy in humans.
Review
GLP-1 receptor agonists and ocular disease: Therapeutic promise, mechanistic insights and emerging safety signals · Drug discovery today · 24 Aug 2026